PayerTalkCE Presents: Current Strategies to Optimize Clinical, Economic, and Humanistic Outcomes in Multiple Sclerosis

Learn About:

The role of neuroinflammation in the development and progression of MS
Emerging MS disease-modifying therapies
The importance of MS subtype, presence of comorbidities, and patient preference

Expert Faculty Presenters


	Janna Evans, PharmD Clinical Account Consultant Pharmacist Blue Cross and Blue Shield Texas Click here for biography

	Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography

	Annette F. Okai, MD, FAAN Director, Neuroimmunology and Multiple Sclerosis Research North Texas Institute of Neurology and Headache Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, specialty pharmacists, registered nurses, quality directors, medical directors, and other managed care professionals.

Statement of Need/Program Overview
Thirty years ago, there were no approved therapies for multiple sclerosis (MS). Today, there are over a dozen disease modifying therapies (DMTs) proven to reduce the frequency of relapses and accumulation of disability reflecting a major advance in the understanding of immune responses that drive the disease. Despite this progress, the limited effectiveness of current therapeutics at controlling neuroinflammation within the central nervous system (CNS) and halting MS progression is a significant unmet need. This PayerTalkCE symposium will include a multidisciplinary faculty discussion to identify mechanisms underlying the neuroinflammation observed in MS and review clinical trial data from emerging MS DMTs that target CNS inflammation. The panel will also assess the importance of considering disease subtype, type and severity of comorbidities, and patient preference when recommending MS treatment.

Educational Objectives
After completing this activity, the participant should be better able to:

Understand the role of neuroinflammation in the development and progression of MS
Know how to incorporate emerging MS disease-modifying therapies that target neuroinflammation into clinical practice by evaluating the mechanism of action and safety and efficacy data
Utilize MS subtype, presence of comorbidities, and patient preference when recommending MS treatment regimens

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-078-L01-P
Activity Type: Knowledge-based

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

*Name of Working Group Members/Planners*	*Reported Financial Relationship*
Janna Evans, PharmD	Nothing to disclose.
Dana McCormick, RPh, FAMCP	Nothing to disclose.
Annette F. Okai, MD, FAAN	Consulting fees (ex.advisory boards): Sanofi Genzyme, Genentech, Biogen, Novartis, EMD Serono Contracted Research: Sanofi Genzyme, Genentech, Biogen

The PACE planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.
Please note: Registration for AMCP 2024 is NOT required to attend this symposium.